The number of FDA-approved biosimilars has grown substantially across oncology, immunology, and other high-cost biologic therapeutic categories, and hospital pharmacy supply chain teams are increasingly building dedicated biosimilar strategy rather than evaluating each new biosimilar approval as an isolated formulary decision.
Why This Needs Its Own Strategy
- Multiple biosimilars for the same reference product now compete for formulary position in many categories, requiring genuine comparative evaluation rather than a simple originator-versus-single-alternative decision
- Interchangeability designation varies by product and affects both clinical workflow and pharmacy substitution authority, adding a layer of complexity beyond simple price comparison
- Manufacturer rebate and contracting structures for biosimilars differ meaningfully from small-molecule generics, requiring pharmacy supply chain teams to build new contract evaluation expertise
The Cost Opportunity
Biosimilar categories with robust competition among multiple products have seen meaningful price erosion relative to the original reference biologic, representing one of the larger available cost-reduction opportunities in current pharmacy supply chain management — but only for facilities that actively manage formulary conversion rather than defaulting to whatever product a given prescriber initially selects.
Building the Conversion Process
Facilities capturing the most value from biosimilar availability typically run active, pharmacy-led formulary conversion programs with defined clinical criteria and prescriber communication plans, rather than relying on passive biosimilar availability alone to drive adoption — passive availability without active conversion effort tends to produce much slower uptake than the cost opportunity would justify.
Facilities managing pharmacy supply strategy can review Healix Medical Supply's pharmacy supply catalog.
